Group 5 Pulmonary Hypertension
This patient has Group 5 pulmonary hypertension (PH with unclear and/or multifactorial mechanisms), which is the classification for all sickle cell disease-associated pulmonary hypertension. 1
Classification Rationale
The American Thoracic Society guidelines explicitly state that pulmonary hypertension in sickle cell disease has been placed within Group 5 PH due to the heterogeneous hemodynamics observed across patients 1. This classification applies regardless of whether the hemodynamic profile shows predominantly precapillary, postcapillary, or mixed features.
Hemodynamic Profile Analysis
Your patient's specific hemodynamics reveal:
- mPAP 28 mmHg (meets PH definition of ≥25 mmHg by 2014 criteria) 1
- PCWP 16 mmHg (elevated, >15 mmHg)
- PVR 1.49 WU (below the 2 WU threshold for "high" PVR) 1
This represents postcapillary pulmonary hypertension within the Group 5 classification
The guidelines define postcapillary PH in SCD as occurring when PAWP/PCWP is >15 mmHg without an increase in PVR 1. Your patient's PVR of 1.49 WU falls below the ~2 WU (160 dyn·s·cm⁻⁵) threshold that indicates elevated resistance 1.
Clinical Significance of Hypoxia
The presence of significant hypoxia is particularly important here. Hypoxia is one of the five interacting pathophysiologic axes in SCD-PH (along with anemia/high-output, hemolysis, inflammation, and thrombosis) 2. Chronic hypoxia can:
- Drive pulmonary vascular remodeling
- Contribute to left ventricular diastolic dysfunction
- Amplify the postcapillary phenotype
- Potentially evolve toward combined pre- and postcapillary features over time 2
Important Prognostic Consideration
Recent data from the ETENDARD study identifies PVR ≥1.5 WU as a critical mortality threshold in SCD patients with mPAP >20 mmHg 3. Your patient's PVR of 1.49 WU sits just below this threshold, but the presence of significant hypoxia and elevated PCWP still confers increased mortality risk compared to patients without PH.
Common Pitfall to Avoid
PCWP may underestimate true left ventricular end-diastolic pressure (LVEDP) in sickle cell disease 4. One study found PCWP misclassified 50% of SCD patients, significantly underestimating LVEDP. This means your patient could have more severe left heart involvement than the PCWP of 16 mmHg suggests, potentially explaining the postcapillary hemodynamics.
Why Not Other Groups?
- Not Group 1 (pulmonary arterial hypertension): PVR is not elevated
- Not Group 2 (left heart disease): While there's postcapillary physiology, SCD-PH is specifically classified as Group 5 due to its multifactorial mechanisms 1
- Not Group 3 (lung disease/hypoxia): Despite hypoxia being present, SCD itself drives the classification
- Not Group 4 (chronic thromboembolic): No indication of this etiology
The Group 5 classification acknowledges that SCD-PH involves complex, overlapping mechanisms including hemolysis-induced endothelial dysfunction, chronic anemia with high cardiac output, hypoxia, inflammation, and potential microthrombosis—all contributing to the observed hemodynamic profile 2, 5, 6.